E. R. Squibb Sons, Inc.

American Home Products Corporation

James L Bergey

Theodore S Sulkowski

Albert A Mascitti

Gary J Grover

Cary S Yonce

Werner Tschollar

James C Kawano

John Krapcho

A method is provided for slowing the progression of atherosclerosis in hypertensive or normotensive patients and reducing or eliminating atherosclerotic lesions in such patients by administering a combination of a cholesterol lowering drug such as pravastatin, and an ACE inhibitor, especially one containing a mercapto moiety, such as captopril or zofenopril.

Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor

A method is provided for preventing or reducing the risk of hypertension in normotensive patients having insulin resistance by administering a cholesterol lowering drug, such as pravastatin, alone or in combination with an ACE inhibitor, especially one containing a mercapto moiety, such as captopril or zofenopril.

Method for preventing onset of hypertension employing a cholesterol

A method is provided for treating hypertension in normotensive patients having insulin resistance by administering a cholesterol lowering drug, such as pravastatin, alone or in combination with an ACE inhibitor, especially one containing a mercapto moiety, such as captopril or zofenopril.

Method for treating hypertension employing a cholesterol lowering drug

A novel pharmaceutical composition and method is disclosed for the treatment of cardiovascular diseases, e.g. myocardial ischemia and/or arrhythmia. The method and composition include an effective amount of a compound of the formula ##STR1## wherein X, Y, R, R.sub.1, A, A', m, n, p, p' and B are as defined herein.

Pharmaceutical composition and method for treating cardiovascular

Zofenopril, fosinopril, (S)-1-[6-amino-2-[[hydroxy(4-phenylbutyl)phosphinyl]oxy]-1-oxohexyl]-L-pro line or a pharmaceutically acceptable salt thereof alone or in combination with a thrombolytic, antiarrhythmic, or antifibrillatory agent is employed to reduce pre- and post-ischemic myocardial arrhythmias and fibrillations as well as reducing arrhythmias associated with congestive heart failure.

Method of reducing pre- and post-ischemic myocardial arrhythmias and

Zofenopril, fosinopril, (S)-1-[6-amino-2-[[hydroxy (4-phenylbutyl) phosphinyl]oxy]-1-oxohexyl]-L-proline or a pharmaceutically acceptable salt thereof alone or in combination with a thrombolytic, antiarrhythmic, or antifibrillatory agent is employed to reduce pre-and post- ischemic myocardial arrhythmias and fibrillations as well as reducing arrhythmias associated with congestive heart failure.

Method of reducing pre-and post-ischemic myocardial arrhythmias and

Zofenopril, fosinopril, (S)-1-[6-amino-2-[[hydroxy(4-phenylbutyl)phosphinyl]oxy]-oxohexyl]-L-proli ne or a pharmaceutically acceptable salt thereof alone or in combination with a thrombolytic, antiarrhythmic, or antifibrillatory agent is employed to reduce pre- and post- ischemic myocardial arrhythmias and fibrillations as well as reducing arrhythmias associated with congestive heart failure.

Compounds of the formula: ##STR1## wherein: Y is 2,6-dimethylphenyl, 2,5-dimethylphenyl, 5-bromo-2-methylphenyl, or 5-chloro-2-methylphenyl; and

N-3-Propenylaminopropyl-N'-phenylureas

1,4,5,6,7,8-Hexahydro-2-alkyl-4-pentafluorophenyl-5-oxo-1,7-naphthyridine-3 -carboxylic acid esters and pharmaceutically acceptable salts thereof are useful antihypertensive agents.

Antihypertensive agents

Compounds of the formula: ##STR1## wherein: Y is 2,6-dimethylphenyl, 2,5-dimethylphenyl, [5-bromo-2-methylphenyl], or 5-chloro-2-methylphenyl; and

Anti-arrhythmic N-[3-alkylaminopropyl]-N'-phenylureas

1,4,5,6,7,8-hexahydro-2-alkyl-4-aryl-5-oxo-1,7-naphthyridine-3-carboxylic acid esters and pharmaceutically acceptable salts thereof are useful antihypertensive agents.

Method of suppressing cardiac arrhythmias compounds of the formula: ##STR1## wherein: Y is 2,6-dimethylphenyl, 2,5-dimethylphenyl, 5-bromo-2-methylphenyl, or 5-chloro-2-methylphenyl; and

Method of suppressing cardiac arrhythmias

Compounds of the formula: ##STR1## wherein: Y is 2,6-dimethylphenyl, 2,5-dimethylphenyl, 3,5-dimethylphenyl, 2-chloro-6-methylphenyl, or 5-chloro-2-methylphenyl; and

Growing community of inventors

Lansdale, PA, United States of America

James L Bergey